5Locker GY, Hamiton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer[J].J Clin Oncol, 2006, 24 : 5313 - 5327.
6Murray MD, Burton FR, Di Bisceglie AM, Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis[J]. J Clin Gastroenterol 2007, 41 : 115 - 117.
7Mohan V, Premalatha G and Pitchumoni CS. Pancreatic diseases and diabetes. In: Textbook of diabetes. Eds: Pickup JC and Williams G. Third edition [J]. USA: Blackwell Publishing, 2003, 28 : 1 - 15.
8Benhamou PY, Vuillez JP, Halimi S, Meffre G, Bachelot I. Influence of metabolic disturbances of diabetes mellitus on serum CA 19- 9 tumor marker [J].Diabete Metab 1991, 17 : 39 - 43.
9Banfi G, Ardemagni A, Bravi S, Pacchioni M, Bonini P. Are diabetic metabolic compenstion and CA19.9 really correlated [J]. Int J Biol Markers 1996, 11:207- 210.
10Uygur-Bayramicli O, Dabak R, Orbay E, Dolapcioglu C, Sargin M, Kilicoglu G, Guleryuzlu Y, Mayadagli A. Type 2 diabetes mellitus and CA 19 - 9 levels.
